JP2001510795A5 - - Google Patents

Download PDF

Info

Publication number
JP2001510795A5
JP2001510795A5 JP2000503831A JP2000503831A JP2001510795A5 JP 2001510795 A5 JP2001510795 A5 JP 2001510795A5 JP 2000503831 A JP2000503831 A JP 2000503831A JP 2000503831 A JP2000503831 A JP 2000503831A JP 2001510795 A5 JP2001510795 A5 JP 2001510795A5
Authority
JP
Japan
Prior art keywords
levobupivacaine
surgery
composition
composition according
dosage formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000503831A
Other languages
English (en)
Other versions
JP2001510795A (ja
Filing date
Publication date
Priority claimed from GBGB9715462.9A external-priority patent/GB9715462D0/en
Priority claimed from GBGB9722022.2A external-priority patent/GB9722022D0/en
Priority claimed from GBGB9810427.6A external-priority patent/GB9810427D0/en
Application filed filed Critical
Priority claimed from PCT/GB1998/002170 external-priority patent/WO1999004772A2/en
Publication of JP2001510795A publication Critical patent/JP2001510795A/ja
Publication of JP2001510795A5 publication Critical patent/JP2001510795A5/ja
Pending legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】 大手術の前にヒト患者を麻酔するための、少なくとも200mgのレボブピバカインを含む組成物。
【請求項2】 大手術の前にヒト患者を麻酔するための、患者へ少なくとも3mg/kgのレボブピバカインを投与するためのものである、レボブピバカインを含む組成物。
【請求項3】 投与量が3〜5mg/kgである請求項2記載の組成物。
【請求項4】 少なくとも225mgのレボブピバカインを含む請求項1記載の組成物。
【請求項5】 少なくとも250mgのレボブピバカインを含む請求項1記載の組成物。
【請求項6】 300mgまでのレボブピバカインを含む請求項1、4または5のいずれかに記載の組成物。
【請求項7】 大手術が、整形外科手術、手足血管の手術、形成手術、やけど治療、上顎骨顔面手術、腹部または他の一般手術、扁桃摘出手術、虫垂切除、子宮摘出、ヘルニア治療、眼病手術および緊急手術から選択される請求項1から6いずれかに記載の組成物。
【請求項8】 レボブピバカインがデキストロブピバカインに対して少なくとも90%のエナンチオマー過剰率で存在する請求項1から7いずれかにいずれかに記載の組成物。
【請求項9】 少なくとも200mgのレボブピバカインを含む単位投与製剤。
【請求項10】 少なくとも225mgのレボブピバカインを含む請求項9記載の投与製剤。
【請求項11】 少なくとも250mgのレボブピバカインを含む請求項9記載の投与製剤。
【請求項12】 300mgまでのレボブピバカインを含む請求項9〜11のいずれかに記載の投与製剤。
【請求項13】 少なくとも200mgのレボブピバカインを含む医薬送達システム。
【請求項14】 少なくとも225mgのレボブピバカインを含む請求項13記載のシステム。
【請求項15】 少なくとも250mgのレボブピバカインを含む請求項13記載のシステム。
【請求項16】 300mgまでのレボブピバカインを含む請求項13〜15のいずれかに記載のシステム。
【請求項17】 注射器である請求項13〜16のいずれかに記載のシステム。
JP2000503831A 1997-07-22 1998-07-21 レボブピバカインとその使用 Pending JP2001510795A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9715462.9A GB9715462D0 (en) 1997-07-22 1997-07-22 levobupivacaine and its use
GB9715462.9 1997-07-22
GBGB9722022.2A GB9722022D0 (en) 1997-10-17 1997-10-17 Levobupivacaine and its use
GB9722022.2 1997-10-17
GB9810427.6 1998-05-14
GBGB9810427.6A GB9810427D0 (en) 1998-05-14 1998-05-14 Levobupivacaine and its use
PCT/GB1998/002170 WO1999004772A2 (en) 1997-07-22 1998-07-21 Use of levobupivacaine

Publications (2)

Publication Number Publication Date
JP2001510795A JP2001510795A (ja) 2001-08-07
JP2001510795A5 true JP2001510795A5 (ja) 2006-01-05

Family

ID=27268945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000503831A Pending JP2001510795A (ja) 1997-07-22 1998-07-21 レボブピバカインとその使用

Country Status (12)

Country Link
US (2) US6069155A (ja)
EP (1) EP0998287B1 (ja)
JP (1) JP2001510795A (ja)
AT (1) ATE239474T1 (ja)
AU (1) AU739510B2 (ja)
BR (1) BR9802537A (ja)
CA (1) CA2294921C (ja)
DE (1) DE69814394T2 (ja)
DK (1) DK0998287T3 (ja)
ES (1) ES2198731T3 (ja)
PT (1) PT998287E (ja)
WO (1) WO1999004772A2 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6376754B1 (en) * 1997-03-07 2002-04-23 Asgrow Seed Company Plants having resistance to multiple herbicides and its use
EP1030652B1 (en) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
DE69940735D1 (de) 1998-07-17 2009-05-28 Pacira Pharmaceuticals Inc Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
ES2269378T3 (es) * 2000-03-24 2007-04-01 Stephen Brushey Cateter para anestesia.
US7805188B2 (en) * 2000-03-24 2010-09-28 Micor, Inc. Anesthesia conduction catheter for delivery of electrical stimulus
BR0002246A (pt) * 2000-04-06 2003-04-15 Cristalia Prod Quimicos Farm Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis
US20030096000A1 (en) * 2001-05-31 2003-05-22 Solis Rosa Maria Encapsulation of nanosuspensions in liposomes and microspheres
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
WO2004011054A2 (en) 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
US8252303B2 (en) * 2002-07-31 2012-08-28 Durect Corporation Injectable depot compositions and uses thereof
WO2004060147A2 (en) * 2002-12-31 2004-07-22 The Board Of Trustees Of The University Of Illinois Tissue and organ preservation, protection and resuscitation
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
WO2023215604A1 (en) 2022-05-05 2023-11-09 Pfof Llc Anesthetic nerve block and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695576A (en) * 1984-07-09 1987-09-22 Astra Lake Medel Aktiebolag L-N-n-propylpipecolic acid-2,6-xylidide
ATE210982T1 (de) * 1993-10-13 2002-01-15 Darwin Discovery Ltd Analgetisches mittel und dessen verwendung
GB9321061D0 (en) * 1993-10-13 1993-12-01 Chiroscience Ltd Analgestic agent and its use
US5849763A (en) * 1993-10-13 1998-12-15 Darwin Discovery Limited Use of levobupivacaine as an anesthetic agent
AU704806B2 (en) * 1995-04-13 1999-05-06 Darwin Discovery Limited Levobupivacaine and its use as an anaesthetic in pregnant women
GB9704352D0 (en) * 1997-03-03 1997-04-23 Chiroscience Ltd Levobupivacaine and its use

Similar Documents

Publication Publication Date Title
JP2001510795A5 (ja)
RU2355387C2 (ru) Трансдермальный гранисетрон
ES2290120T3 (es) Procedimientos para mejorar la dimension y el aspecto de una herida.
RU2002127804A (ru) Лекарственная система для лечения осложнений, связанных с диабетом, и невропатии, и их применения
CN103491778B (zh) 1‑甲基‑n‑(2,6‑二甲苯基)‑2‑哌啶甲酰胺的皮肤用药物组合物及其使用方法
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
JP2002500180A5 (ja)
JP2005501110A5 (ja)
KR101900520B1 (ko) 복합 조성물
JP2002528502A5 (ja)
HK1079703A1 (zh) 通過靜脈施用鹵化揮發性麻醉藥保護心臟和保護神經的方法
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
JP2004537500A5 (ja)
KR880007073A (ko) 의 약 품
JP2002544233A5 (ja)
O'Hanlon et al. Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia
JP3792251B2 (ja) 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用
CA2450915A1 (en) Use of levosimendan and beta-adrenergic receptor antagonist for the treatment of heart failure
RU2008126108A (ru) Фармацевтическая композиция для лечения остеоартрита, содержащая клодроновую кислоту и гиалуроновую кислоту
Cassuto et al. Potent inhibition of burn pain without use of opiates
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
JP2001510794A5 (ja)